XML 38 R29.htm IDEA: XBRL DOCUMENT
v3.23.3

STOCK OPTIONS AND WARRANTS (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2023 | Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |
SCHEDULE OF STOCK OPTIONS | SCHEDULE OF STOCK OPTIONS
|  | 2023 |
|  | Shares |  |  | Price (1) |  |  | Term (2) |
Outstanding, at December 31, 2022 |  |  | 145 |  |  | $ | 72.25 |  |  |  | 3.3 |
Granted |  |  | 16 |  |  |  | - |  |  |  |  |
Forfeited |  |  | (24 | ) |  |  | - |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  |  |
Outstanding, at September 30 |  |  | 137 | (3) |  |  | 69.75 |  |  |  | 3.7 |
Exercisable, at September 30 |  |  | 88 | (4) |  |  | 85.75 |  |  |  | 3.1 |
(1) | Represents the weighted average exercise price.
(2) | Represents the weighted average remaining contractual term until the stock options expire.
(3) | As of September 30, 2023, the aggregate intrinsic value of stock options outstanding was $0.
(4) | As of September 30, 2023, the aggregate intrinsic value of exercisable stock options was $0.
| SCHEDULE OF STOCK OPTIONS
|  | 2022 |  |  | 2021 |
|  | Shares |  |  | Price(1) |  |  | Term(2) |  |  | Shares |  |  | Price(1) |  |  | Term(2) |
Outstanding, beginning of year |  |  | 114 |  |  | $ | 124.00 |  |  |  | 3.3 |  |  |  | 92 |  |  | $ | 121.00 |  |  |  | 1.3 |
Grants |  |  | 79 |  |  |  | 25.25 |  |  |  |  |  |  |  | 39 |  |  |  | 130.75 |  |  |  |  |
Forfeited/cancelled |  |  | (48 | ) |  |  | 134.50 |  |  |  |  |  |  |  | (9 | ) |  |  | 156.25 |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  |  |  |  |  | (8 | )(3) |  |  | 41.25 |  |  |  |  |
Outstanding, at December 31 |  |  | 145 | (4) |  |  | 72.25 |  |  |  | 3.3 |  |  |  | 114 | (4) |  |  | 124.00 |  |  |  | 3.3 |
Exercisable, at December 31 |  |  | 90 | (5) |  |  | 75.50 |  |  |  | 3.4 |  |  |  | 76 | (5) |  |  | 113.25 |  |  |  | 2.7 |
(1) | Represents the weighted average exercise price.
(2) | Represents the weighted average remaining contractual term until the stock options expire.
(3) | On the respective exercise dates as of December 31, 2021, the aggregate intrinsic value of shares of Common Stock issued upon exercise of stock options amounted to $0.6 million.
(4) | As of December 31, 2022 and 2021, the aggregate intrinsic value of stock options outstanding was $0.
(5) | As of December 31, 2022 and 2021, the aggregate intrinsic value of exercisable stock options was $0.
SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS USED IN THE FAIR VALUE |  | SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS USED IN THE FAIR VALUE
|  | 2022 |  |  | 2021 |
Grant date closing price of common stock |  | $ | 25.25 |  |  | $ | 130.75 |
Expected term (years) |  |  | 3.5 |  |  |  | 3.5 |
Risk-free interest rate |  |  | 3.4 | % |  |  | 0.8 | %
Volatility |  |  | 112 | % |  |  | 141 | %
Dividend yield |  |  | 0 | % |  |  | 0 | %
SCHEDULE OF WARRANT OUTSTANDING | The following table sets forth activity with respect to the Company’s warrants to purchase Common Stock for the nine months ended September 30, 2023 (shares in thousands): SCHEDULE OF WARRANT OUTSTANDING
|  | 2023 |
|  | Shares |  |  | Price (1) |  |  | Term (2) |
Outstanding, at December 31, 2022 |  |  | 145 |  |  | $ | 136.8 |  |  |  | 2.5 |
Grants of warrants: |  |  |  |  |  |  |  |  |  |  |  |
Consultants for services |  |  | 86 | (3) |  |  |  |  |  |  |  |
Private placement |  |  | 453 | (4) |  |  |  |  |  |  |  |
Exercised |  |  | (187 | )(5) |  |  |  |  |  |  |  |
Forfeited |  |  | (2 | ) |  |  |  |  |  |  |  |
Outstanding, September 30 |  |  | 496 | (6) |  |  | 59.5 |  |  |  | 5.7 |
Exercisable, September 30 |  |  | 429 | (7) |  |  | 62.2 |  |  |  | 3.9 |
(1) | Represents the weighted average exercise price.
(2) | Represents the weighted average remaining contractual term until the warrants expire.
(3) | In February 2023, the Company granted warrants to consultants in exchange for business development, product development and distribution. Warrants issued in February 2023 provide for the purchase of an aggregate of 84,000 shares of common stock at an exercise price of $22.75 and $15.25 per share with a fair value of approximately $1.3 million which will be recognized upon the achievement of performance metrics and milestones. In June 2023, the Company granted warrants to consultants in exchange for services. Warrants issued in June 2023 provide for the purchase of an aggregate of 1,500 shares of common stock at an exercise price of $10.25 per share at a fair value of approximately $0.1 million which will be recognized upon the achievement of performance metrics and milestones. In August 2023, the Company granted warrants to consultants in exchange for services. Warrants issued in August 2023 provide for the purchase of an aggregate of 900 shares of common stock at an exercise price of $8.50 per share at a fair value of approximately less than $0.1 million which will be recognized per the vesting schedule. For the nine months ended September 30, 2023, the Company recognized expense of $0.7 million.
(4) | In January 2023, the Company granted warrants in connection with a private placement consisting of pre-funded warrants to purchase up to an aggregate of 186,667 shares of common stock at an exercise price of $0.0001 per share, and warrants to purchase up to an aggregate of 266,667 shares of common stock at an exercise price of $30 per share with a fair value of approximately $14.5 million which was recognized as warrant liability at the time of issuance.
(5) | In March 2023, the Company issued an aggregate of 186,667 shares of common stock from the exercise of warrants previously issued in January 2023.
(6) | As of September 30, 2023, the aggregate intrinsic value of warrants outstanding was $0.
(7) | As of September 30, 2023, the aggregate intrinsic value of warrants exercisable was $0.
| The following table sets forth activity with respect to the Company’s warrants to purchase Common Stock for the years ended December 31, 2022 and 2021 (shares in thousands): SCHEDULE OF WARRANT OUTSTANDING
|  | 2022 |  |  | 2021 |
|  | Shares |  |  | Price(1) |  |  | Term(2) |  |  | Shares |  |  | Price(1) |  |  | Term(2) |
Outstanding, beginning of year |  |  | 102 |  |  | $ | 186.00 |  |  |  | 3.1 |  |  |  | 78 |  |  | $ | 109.50 |  |  |  | 4.2 |
Grants of warrants: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consultants for services |  |  | 42 | (3) |  |  | 26.25 |  |  |  |  |  |  |  | 15 |  |  |  | 189.00 |  |  |  |  |
Acquisition of assets |  |  | - |  |  |  |  |  |  |  |  |  |  |  | 9 |  |  |  | 189.00 |  |  |  |  |
Outstanding, December 31 |  |  | 144 | (4) |  | $ | 137.50 |  |  |  | 2.6 |  |  |  | 102 | (4) |  | $ | 186.00 |  |  |  | 3.1 |
Exercisable, December 31 |  |  | 124 | (5) |  | $ | 145.00 |  |  |  | 2.5 |  |  |  | 92 | (5) |  | $ | 185.50 |  |  |  | 3.1 |
(1) | Represents the weighted average exercise price.
(2) | Represents the weighted average remaining contractual term until the warrants expire.
(3) | In February, 2022, the Company granted warrants to consultants in exchange for marketing, business development, investor relations and communication services. Warrants issued in February 2022 provide for the purchase of an aggregate of 3,200 shares of Common Stock and are exercisable at $81.75 per share. The aggregate fair value of the February warrants amounted to $0.1 million, which is being recognized over the period that the services are provided. In May, 2022, the Company granted warrants to consultants in exchange for marketing and business development services. Warrants issued in May 2022 provide for the purchase of an aggregate of 5,200 shares of Common Stock and are exercisable at $32.25 per share. The aggregate fair value of the May warrants amounted to $0.1 million, which is being recognized over the period that the services are provided. Warrants issued in December 2022 provide for the purchase of an aggregate of 34,000 shares of Common Stock and are exercisable at $12.00 per share. The aggregate fair value of the December warrants amounted to $0.2 million, which is being recognized over the period that the services are provided or according to the vesting schedule. For the year ended December 31, 2022, the Company recognized expense of $0.7 million.
(4) | As of December 31, 2022 and 2021, the aggregate intrinsic value of warrants outstanding was $0.
(5) | As of December 31, 2022 and 2021, the aggregate intrinsic value of warrants exercisable was $0.
Warrant [Member] |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |
SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS USED IN THE FAIR VALUE | SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS USED IN THE FAIR VALUE
|  | 2023 |
Measurement date closing price of Common Stock (1) |  | $ | 18.25 |
Contractual term (years) (2) |  |  | 5.0 |
Risk-free interest rate |  |  | 4.2 | %
Volatility |  |  | 102 | %
Dividend yield |  |  | 0 | %
| (1) | Weighted average grant price.
| (2) | The valuation of warrants is based on the expected term.
| SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS USED IN THE FAIR VALUE
|  | 2022 |  |  | 2021 |
Measurement date closing price of Common Stock (1) |  | $ | 19.75 |  |  | $ | 186.00 |
Contractual term (years) (2) |  |  | 5.0 |  |  |  | 2.6 |
Risk-free interest rate |  |  | 3.6 | % |  |  | 0.3 | %
Volatility |  |  | 102 | % |  |  | 138 | %
Dividend yield |  |  | 0 | % |  |  | 0 | %
| (1) | Weighted average grant price.
| (2) | The valuation of warrants is based on the contractual term of the warrant rather than the expected term.
Share-Based Payment Arrangement, Option [Member] |  |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |  |
SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS USED IN THE FAIR VALUE | SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS USED IN THE FAIR VALUE
|  | September 30, 2023 |
Grant date closing price of Common Stock |  | $ | 10.00 |
Expected term (years) |  |  | 3.5 |
Risk-free interest rate |  |  | 3.9 | %
Volatility |  |  | 102 | %
Dividend yield |  |  | 0 | %

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the change in stock options. + References No definition available. + Details
Name: | us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |